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Abstract 
Objective: The aim of this study was to validate the revised SenTec V-SignTM 2 sensor for 
combined non-invasive continuous assessment of pulse rate, pulse oximetry (SpO2) and 
transcutaneous carbon dioxide tension (PtcCO2) in adults after cardiac surgery. 
Design: prospective clinical study 
Setting: University Hospital, single-center 
Participants: twenty adult patients after cardiac surgery, aged 36 to 84 years,  
Interventions: SpO2 and PtcCO2 values of three V-SignTM 2 sensors attached at the ear-lobe, 
forehead and cheek and SpO2 values of the Nellcor Durasensor (model DS-100A) were 
compared with simultaneous measurements of blood gases and end-expiratory carbon dioxide. 
Measurements and Main Results:  Measurements were performed during periods of hyper-, 
normo- and hypocapnia and then at 30 min intervals up to 5 hours. Bland-Altman analysis and 
simple regression analysis were used. 
Results: Detection failures for PtcCO2 were 0.3 to 1.3%, for SpO2 10 to 25%, and for pulse 
rate 5 to 10%. The V-SignTM 2 ear-lobe sensor provided the best results. Mean bias and limits 
of agreement for PtcCO2ear and PaCO2 were +1.1 and  -3.4 / +5.5 mmHg). Drift of PtcCO2 
was negligible at all locations.  Mean bias and limits of agreement of  V-Sign SpO2ear and 
SaO2 as well as V-Sign pulse rate and ECG were -1.7% and -6.8 / + 3.9%, and 1.2 bpm and -
3.3 / +5.8 bpm. End-expiratory carbon dioxide showed a weak correlation with PaCO2 (r2 = 
0.47). 
Conclusions: Transcutaneous capnometry using the revised V-SignTM 2 sensor at the earlobe 
is a reliable monitoring tool during the recovery period of patients after cardiac surgery. This 
approach has the potential to reduce the number of arterial blood gas samples.  
 
Key Words: non-invasive monitoring, combined transcutaneous PCO2 and SpO2, digital ear 
sensor, cardiac surgery intensive care unit 
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Introduction 
 
Transcutaneous continuous partial carbon dioxide (PtcCO2) sensors have been used more than 
twenty years [1] and the devices have been continuously improved. At present, all 
commercially available PtcCO2 sensors are electrochemical in nature [2].  
Initially, PtcCO2 sensors were mainly utilized in neonatology and in critically ill infants in 
combination with the measurement of transcutaneous partial oxygen tension [3, 4]. Currently, 
combined assessment of PtcCO2 and partial oxygen tension using a single earlobe clip sensor 
is increasingly used in adult patients during noninvasive mechanical ventilation [5], 
transportation of critically ill adults [6], bronchoscopy [7], sleep studies [8, 9] and pulmonary 
stress testing [10]. However, sensor preparation, positioning, taping, and the necessity for 
repeated calibration and repeated changes of the sensor’s location because of drifting of the 
PtcCO2 signal made handling cumbersome [4]. Additionally, the results of recently performed 
studies in neonates, infants and adults are controversial in terms of the reliability of these 
devices [6, 11-13]. In adults, clip sensors at the earlobe are routinely used because of its 
intense capillary perfusion. During haemodynamic instability, however, reliability of PtcCO2 
earlobe clip sensors may be restricted because of centralisation of perfusion. Secondary to the 
earlobe, other skin locations such as the forehead and the cheek might provide adequate 
perfusion conditions for transcutaneous detection of PtcCO2 and SpO2 in critically ill adult 
patients.  
Most recently a revised V-SignTM sensor (V-SignTM 2 sensor, SenTec Digital Monitoring 
System [SDM]; SenTec AG, Therwil, Switzerland) has been designed by the manufacturer.  
Earlobe clips as well as attachment ring-clips are available for sensor application at different 
sites of the body. The V-SignTM 2 sensor measures PtcCO2, pulse rate and arterial oxygen 
saturation (SpO2) continuously and noninvasively. It combines the elements of a temperature-
controlled Stow-Severinghaus pH-sensitive glass electrode and a conventional pulse oximetry 
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sensor. Severinghaus type electrodes always show a certain amount of drift over time, as the 
electrochemical measurement is influenced by a number of time-varying factors, including 
material selection. One biological reason for signal drift may be the increasing production of 
CO2 in the skin areas surrounding the sensor during rewarming. The revised V-SignTM sensor 
was improved by the material side and the data processing algorithm that characterizes and 
compensates the drift. Drift specific information is directly stored on the digital sensor itself 
(in vivo correction). Additionally the equilibration time has been reduced from until 20 min to 
3 to 10 min with a mean equilibration time of 5 min. The sensor is heated up to 42°C to 
achieve local arterialization of the skin at the site of PtcCO2 monitoring. Prior to application 
of the sensor to the patient’s skin, an automatic calibration of the sensor is performed in vitro. 
Afterwards, the sensor is mounted at the skin and the first measurement is performed after 
allowing a 10-min equilibration time.  
The primary aim of this study was to validate the data acquired with the V-SignTM 2 sensor at 
the earlobe, forehead and cheek in comparison to arterial carbon dioxide tension (PaCO2) and 
arterial oxygen saturation (SaO2), measured by co-oximetry, and pulse rate (PR) derived from 
the electrocardiogram in critically ill patients after cardiac surgery. The secondary aim was to 
investigate the safety, feasibility and medium term precision of the new V-SignTM 2 sensor at 
the different sensor locations. 
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Material and Methods 
 
With ethics committee approval and written informed consent, 20 patients scheduled for 
elective cardiac surgery were enrolled in this prospective single-centre trial. Exclusion criteria 
were non-German-speaking patients, unstable haemodynamics, arrhythmias, and age <18 
years. Criteria for terminating a subject’s participation were unstable haemodynamics and/or 
significant arrhythmias, need for re-operation, a serious skin lesion at the measurement site 
and withdrawal of consent by the patient. Before surgery, standard instrumentation included a 
continuous 2-channel ECG (leads II and V5) (Delta Infinity Delta XL Kappa monitor (Dräger 
Medical Systems, Inc. Lübeck, Germany), continuous arterial blood pressure monitoring via a 
fluid-filled catheter system (Baxter Healthcare Corp. Cardiovascular Group Irvine) connected 
to the radial artery inserted at the nondominant hand, a triple-lumen central venous catheter 
(Arrow International, Reading, PA) and a 7.5-FG thermistor-tipped, flow-directed pulmonary 
artery catheter (IntelliCath Baxter Healthcare Corporation Edwards Critical Care Division), 
introduced through an 8.5-FG introducer (Arrow International), inserted into the right internal 
jugular vein and connected to a cardiac output vigilance® computer system (9520A Baxter 
Healthcare Corporation).  
After arrival of the patient in the ICU, V-SignTM 2 sensors were attached according to the 
manufacturer’s directions to the inside of the left earlobe using an adhesive Ear-Clip 
(PtcCO2ear, V-Sign SpO2ear, V-Sign PRear), to the forehead (PtcCO2forehead, V-Sign SpO2forehead, 
V-Sign PRforehead) and to the cheek (PtcCO2cheek, V-Sign SpO2cheek, V-Sign PRcheek) each 
affixed with an adhesive ring-clip. Each probe was connected to one of three SenTec Digital 
Monitoring Systems (SDMS, Software Prereleases SMB V7.0 / MPB V5.0, SentTec AG, 
Therwil, Switzerland). As reference method for non invasive, continuous measurements of 
SpO2 and PR, a Nellcor Durasensor (Model DS-100A) was attached to the forefinger of the 
non cannulated hand and connected with the Nellcor’s N-595 Finger clip Pulse Oximeter 
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(Nellcor Puritan Bennett Inc., Pleasanton, CA, USA). Arterial blood samples (BS) were 
drawn from the indwelling radial artery catheter at time points specified in the study protocol. 
PaCO2 was measured at a standard temperature of 37°C, and SaO2 was determined by co-
oximetry (multi-wavelength haemoximetry) (ABL 800, Radiometer Medical A/S, Akandevej 
21 DK-2700 Bronshoj, Denmark). 
All data generated by the three V-SignTM 2 sensors, the Nellcor 595 device, and the vigilance 
computer system [continuous cardiac index and mixed venous oxygen saturation (SvO2)] 
were continuously recorded by means of an online computing system for subsequent plotting 
and off-line statistical data analysis. The time points and the results of the respective blood 
gas and co-oximetry values were also documented in the online computing system. 
In addition, at the time points of the arterial blood samples, all data were recorded off-line on 
a separate protocol sheet. Additional recordings included end-expiratory carbon dioxide 
tension (PECO2), mean arterial pressure (MAP), bolus thermodilution cardiac index (BCI), 
blood temperature, peripheral skin perfusion (I = warm and dry; II = cool; III = cold) and skin 
status at the measurement sites where the V-Sign sensors were attached (0 = no reddening; 1 
= slight reddening; 2 = reddening; 3 = intensive reddening; 4 = blister). 
BCI was measured by injecting 10 ml of iced saline 0.9% with a closed injectate system (CI-
set; Baxter Healthcare Corp.). Injections were distributed randomly throughout the respiratory 
cycle. Thermodilution curves were displayed on a recorder and accepted as correct if the 
shape of the curve fulfilled the criteria of Levett and Replogle [14] and if the injectate 
temperature was <10°C.  
After haemodynamic stabilization in the ICU, arterial blood samples were taken before 
attaching the sensors (BS1), 7.5 min (BS2) and 15 min (BS3) after attaching the sensors 
(equilibration phase). Thereafter, duplicate samples were taken with an interval of 5 min after 
20 min of hyperventilation (target PaCO2 = 4.5 kPa) (BS4 and BS5); after 20 min of 
normoventilation (target PaCO2 = 5.0 kPa) (BS6 and BS7) and after 20 min of hypoventilation 
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(target PaCO2 = 6.5kPa) (BS8 and BS9). Subsequently, one sample was taken every half hour 
until five hours after starting the trial (BS10-BS16). Following data were simultaneously 
collected at the different time points: blood temperature, CCI, N595-ECG, N595-SpO2, PaO2, 
PaCO2, PECO2, PR, SaO2, V-Sign PRear, V-Sign PRforehead, V-Sign PRsheek, V-Sign SpO2ear, V-
Sign SpO2forehead, V-Sign SpO2sheek, PtcCO2ear, PtcCO2forehead, PtcCO2sheek, and MAP. Before 
starting the trial and 2, 4, 8 and 12 h after removing the sensors, peripheral skin perfusion (I = 
warm and dry; II = cool; III = cold) and the local skin status (0 = no reddening; 1 = slight 
reddening; 2 = reddening; 3 = intensive reddening; 4 = blister) at the earlobe, the forehead and 
the cheek were documented.  
 
Statistics 
Power calculation revealed that 20 patients were necessary to estimate variation between and 
within subjects with an accuracy of at least 15%. Bland-Altman analysis [15] was applied to 
assess mean bias and limits of agreement (LOA) (±2 SD of bias) of PaCO2 and PtcCO2, SaO2 
and corresponding values of SpO2 , displayed by the V-SignTM 2 sensors and the Nellcor N-
595 sensor as well as pulse rate derived from the ECG, the V-SignTM 2 sensors and the 
Nellcor N-595. According to the quality criteria for blood gas analyser devices variation in 
the mean bias of PtcCO2 and paCO2 of 3.5% and a variation of LOA of 12.5% was accepted  
as “good”. A mean bias  ± 1 mmHg and LOA  ± 3.5 mmHg were defined as “excellent”. 
Mean bias  ± 1.5 mmHg and LOA  ±5mmHg were defined as good agreement. Values 
outside of these definitions were considered “unsatisfactory”. For comparison V-Sign SpO2 
with SaO2 a good agreement was defined with mean bias ≤ ± 1% and LOA ≤ ± 4%, based on 
the manufacturers precision of measurements of the Nellcor 595 device. Multiple regression 
analysis was performed to determine whether blood temperature, pulse rate, cardiac index, 
skin status mean arterial pressure, the used catecholamines and milrinone significantly 
influenced PtcCO2, PaCO2 and the difference between PtcCO2 and PaCO2 (PtcCO2-PaCO2). A 
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p-value less than 0.05 was considered significant.  Repeated measures ANOVA were used to 
estimate between-subjects and within-subject variations. In addition, simple linear regression 
was performed to assess first differences in transcutaneous and arterial PCO2.  
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Results 
 
Twenty patients were enrolled; their characteristics and procedural parameters are listed in 
Table 1. Repositioning of the sensors was necessary in five cases for the earlobe sensor, in 
three cases for the forehead ring clip sensor, in one case for the cheek ring clip sensor and in 
three cases for the Nellcor finger clip sensor.  For on line data collection a cable bundle of all 
sensors used was build and placed close the head of the patient. Intensive movement the 
patients was the reason for repositioning the sensors in most of these cases. In two times a 
unrealized old membrane of the sensor had to be changed. Two-hundred-ninety-six data pairs 
of PtcCO2ear and PaCO2, 297 data pairs of PtcCO2forehead and PaCO2, and 299 data pairs of 
PtcCO2cheek and PaCO2 were analysed. Median (range) PtcCO2ear, PtcCO2forehead, PtcCO2cheek 
and PaCO2 were 38.8 (26.9-56.5) mmHg, 38.1 (28.9-56.4) mmHg, 38.0 (28.5-57.8) mmHg 
and 36.7 (27.3-54.7) mmHg, respectively, and PaCO2 values were significantly lower than the 
PtcCO2 values ( 0.005). 
A good agreement of PtcCO2 and PaCO2 was only found with the ear lobe sensor with a mean 
bias of +1.1 mmHg and LOA of -3.4 / + 5.5mmHg (Table 2, Fig 1a-c). with the best 
agreement of PtcCO2ear and PaCO2 during periods of hyper- and hypoventilation with a mean 
bias (LOA) of +1.4 mmHg (-2.3/+5.0 mmHg) and 0.5 mmHg (-3.4/+4.4 mmHg), respectively 
(Table 3).  
In 7 patients an initial overshoot of PtcCO2 was observed at all sensor locations until 8-25 min 
following calibration of the system. At the sample time 6h, PtcCO2 showed no relevant drift at 
the three sensor locations as compared to PaCO2 (Fig 2). Mean bias of PtcCO2 and PaCO2 did 
not correlate with pulse rate, cardiac index, skin status, MAP and blood temperature. No 
significant influence of the applied catecholamines and the milrinone was found to PaCO2, 
PtcCO2 at all locations and the mean bias of them, excepting the mean bias of PtcCO2ear and 
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PaCO2, which was significantly influenced only by the dobutamine dose (r2 = 0.09, p < 
0.001). 
First differences of PtcCO2 and PaCO2 for earlobe, forehead and cheek correlated well with r2 
of 0.81, 0.73 and 0.77, respectively (Fig 3a-c). The corresponding sensitivity/specificity to 
detect changes of PaCO2 was 87/82 %, 79/78 % and 83/78 %, respectively. PECO2 correlated 
only moderately with PaCO2 and the agreement was poor (Table 2). 
SpO2 detection failures of the V-SignTM 2 sensors at the earlobe, the forehead, the cheek and 
of the Nellcor finger clip sensor were observed in 10%, 19%, 25% and 2%, respectively 
(Table 2). Median (range) of V-SignTM 2 SpO2ear, V-SignTM 2 SpO2forehead, V-SignTM 2 
SpO2cheek, N-595 SpO2 and SaO2 were 97.2 (81.7-100) %, 96 (86-100) %, 96.6 (85-100) %, 
99.8 (87.8-100) % and  98.5 (89.2-100), respectively.  
Agreement of V-SignTM 2 SpO2 and SaO2 at all sensor locations was unsatisfactory and V-
SignTM 2 SpO2 underestimated the corresponding SaO2 values determined by co-oximetry, 
particularly in the lower SaO2 range (Table 2, Fig 4a-c). However, the Nellcor device showed 
the smallest detection error and the best agreement with SaO2, represented by a mean bias 
(LOA) of +0.41 (-2.38/+3.19)%, respectively.  
Pulse rate detection failures of the V-SignTM 2 sensors ranged between 5 to 10%, whereas 
only 2% detection failures were observed with the Nellcor device. V-SignTM 2 PR showed a 
good agreement with the ECG at all sensor locations (Fig 5a-c), whereas the agreement of the 
Nellcor device with the ECG was poor (Table 2). No reddening or higher degrees of skin 
irritation were found in any patient neither during the study period nor following removal of 
the sensors even after 12 hours.  
End-expiratory carbon dioxide correlated poorly with PaCO2, had relevant bias and wide 
limits of agreement (Table 2). 
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Discussion 
 
In this study we evaluated accuracy and precision of the recently revised V-SignTM 2 sensor at 
three different sites of application on the head (earlobe, forehead and cheek) in adult patients 
during recovery from cardiac surgery.  
The main results of the study were (i) the best site for PtcCO2 measurement is the earlobe, (ii) 
at the earlobe, an excellent agreement was found between PtcCO2 and PaCO2 with only a 
slight overestimation of PaCO2, (iii) no statically significant drift was observed at either one 
of the three sensor locations, and the sensitivity and specificity to detect changes of PaCO2 
was good, (iv) the rate of detection failures of SpO2 was high, and the agreement of SpO2 
values with SaO2 was unsatisfactory (v) PR detected with the V-SignTM 2 sensor showed an 
excellent agreement at all sensor locations with the ECG-derived PR, but detection failures 
were found in 5 to 10%, with the lowest rate of detection failure at the earlobe.  
Because of the large capillary network and good access way, the earlobe is the most favourite 
site in adults to attach a sensor that uses electrochemical technology for measuring carbon 
dioxide tension transcutaneously. It is well known, that cutaneous microcirculation shows a 
significant heterogeneity [16]. The supraorbital skin region, where the forehead sensor was 
attached, is supplied by the supraorbital artery, a branch of the internal carotid artery. The 
dependency of the supraorbital skin perfusion on the blood flow rate through the internal 
carotid was recently demonstrated by Hove and co-workers[17], using near infra-red 
spectroscopy in patients undergoing carotid endarterectomy. Supraorbital skin perfusion 
seems to be excluded from the centralization of blood flow accompanying low cardiac output 
states and might therefore be an optimal detection surface. For this reason we attached the 
sensors at the earlobe, the forehead and the cheek and expected better detection of PCO2 and 
SpO2 at the forehead. Thus it is surprising and not easily explicable that the earlobe appeared 
to be the best area for applying the electrochemical PtcCO2 and conventional PaO2 sensors in 
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the present investigation. The inflammatory response that was present postoperatively in most 
patients, the necessity of vasopressor support and the lack of centralization might be a 
possible explanation for this finding. Rodriguez and co-workers [11] recently evaluated 
PtcCO2 monitoring in critically ill adults and reported that only major cutaneous 
vasoconstriction considerably influenced the accuracy of PtcCO2 measurements, whereas 
application of catecholamines, respiratory support and mild hypothermia did not exert 
substantial interference. In the present study exploration of the skin status until 12 hours after 
removal the sensors showed no signs of low perfusion.  
Monitors for combined continuous transcutaneous measurements of carbon dioxide tension 
and oxygen saturation have been investigated in recent years in healthy volunteers [18], 
during major surgery [19], in patients with severe pulmonary disease [5, 20] and in critically 
ill adults [11, 12, 21], but the results regarding reliability were not conclusive. In 13 
spontaneously breathing, not intubated patients in the early postoperative period, Fanelli and 
co-workers [21] reported only a unsatisfactory agreement of PtcCO2 measured with a 
previous version of the V-SignTM 2 earlobe sensor and PaCO2 measured by co-oxymetry. The 
study is however limited in its explanatory power, since a small and particularly 
heterogeneous group of patients was included and because of methodological confinement of 
blood sampling. In a previous study [12], using an older version of the V-SignTM 2 earlobe 
sensor, we also found only unsatisfactory agreement of PtcCO2 and PaCO2 and a significant 
drift over the sampling time in patients after cardiac surgery. Contrary to these results, an 
excellent agreement of PtcCO2 and PaCO2 was found in the present investigation with the 
revised V-SignTM 2 sensor attached at the earlobe. The only slight overestimation is in 
agreement with recent literature [5, 20] and is attributed primarily to the anaerobic factor, 
caused by heating the sensor area, and secondary to CO2 production of living epidermal cells. 
During the 6 hours study period, 16 of the 20 patients were breathing spontaneously while 
being supported by a respirator, the lungs of two patients were ventilated, and two patients 
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were extubated three hours after admission. Intra-individual analysis of the agreement 
between PtcCO2 and PaCO2 data pairs collected after extubation of the two patients showed 
no considerable differences to the patients whose lungs were ventilated. These findings are 
supported by a study most recently published by Maniscalco and colleagues [22] and 
performed in severely obese and clinically unstable patients using the TOSCA device (Linde 
Medical Sensors AG, Basel, Switzerland). These authors reported good agreement of PtcCO2 
and PaCO2 in both spontaneously breathing and ventilated patients.  
A considerable drift of PtcCO2 values over time has been reported by several investigators 
[12, 20, 23]. Storre and co-workers [5] demonstrated a considerably improvement in the 
accuracy of a previous version of the V-SignTM 2 earlobe sensor using an off-line drift 
correction for PtcCO2. Mean bias and limits of agreement of PtcCO2 and PaCO2 after 
retrospective drift correction were -2.9 mmHg and -0.8 / + 1.7 mmHg. Using the revised V-
SignTM 2 sensor in the present investigation we found no relevant drift at all three sensor 
locations during the 6 hours sample period. This finding might most probably be explained by 
the systematic revision of the algorithm of V-SignTM technology by the manufacturer, 
including the integration of a new drift correction modus over time (in vivo correction). 
Using the revised V-SignTM 2 sensor, an initial overshoot of the PtcCO2 signal was observed 
in seven of the 20 patients that disappeared after 20 to 25 min. This finding was previously 
reported by several investigators [12, 24] and may be explained by mobilization of high tissue 
CO2 that has accumulated before vasodilatation occurs during artificial heating of the sensor 
area. The short initial period of higher heating temperature of the sensor area incorporated 
into the revised V-Sign technology did not eliminate the overshoot phenomenon in all 
patients.  
The finding, that dobutamine has an impact on the bias PtcCO2ear and PaCO2 might be 
explained by improvement of the microcirculation at the ear lobe, which leads to a higher 
PtcCO2, caused by higher tissue CO2 production. Since dobutamine in this study was only 
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applied in the low dose range, it is not excluded, that doses of dobutamine above the low 
range may significantly interfere with the accuracy of the PtcCO2 measurement at the ear 
lobe.  
PECO2 correlated only moderately with PaCO2 and with PtcCO2 and the agreements were 
poor, indicating that PtcCO2 better detects changes in the ventilation state of the patients than 
PECO2 during the recovery period.  
Most investigators focused their reports on accuracy and precision of PtcCO2, whereas the 
reliability of oxygen saturation measurements was not or less discussed. Rohling and co-
workers [25] reported excellent agreement of transcutaneously measured SpO2 using the 
TOSCA device and SaO2 in anaesthetized adult patients. Similar results were found in 
anaesthetized pediatric patients by Dullenkopf and co-workers [26] with a mean bias and 
limits of agreement of -0.63% and -3.4 / +2.1% respectively. In patients assessed for long-
term oxygen therapy, Schafroth Török and colleagues [20] recently confirmed these results 
using a previous version of the V-SignTM 2 sensor. However, this investigation was performed 
in medical patients with presumably constant body temperature attending lung function tests 
for assessment of home oxygen therapy. In a previous study [12] using the same sensor as 
Schafroth Török and colleagues [20] we reported unacceptably high limits of agreement for 
SpO2 and SaO2 in patients with stable haemodynamics during recovery after cardiac surgery.  
Although detection of transcutaneous oxygen saturation and pulse rate was considerably 
improved with the revised V-SignTM 2 sensor, the rate of detection failure still ranged between 
10 to 25% and thus was too high at all sensor locations. Additionally, the limits of agreement 
of SpO2 did not meet predefined criteria. The best results were found when the revised V-
SignTM 2 sensor was attached at the earlobe, but the rate of detection failures was still 10%.  
In healthy adult volunteers, Mannheimer and colleagues [27] reported statistically significant 
degradation of reading accuracy of SpO2, measured by reflectance pulse oximetry. They 
recommended to attach the sensor at the lower part of the forehead directly over the eyebrow 
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and slightly lateral to the eye to avoid possible impact of vasculature on SpO2 readings. In the 
current investigation we cannot exclude that pulsatile vasculature at the forehead and cheek 
had an impact on accuracy of SpO2 detection. Remarkably, the rate of detection failure for 
pulse rate, measured with the revised V-SignTM 2 sensors, ranged between 5 to 10% and, thus, 
was considerably lower than that for SpO2. The lowest rate of detection failure of 5% and a 
good agreement with a bias of +1.2 bpm and limits of agreement of -3.3 and +5.8 were found 
with the revised sensor attached to the earlobe. The lowest rate of detection failure of 2% for 
SpO2 and PR and an excellent agreement of SpO2 and SaO2 were found with the Nellcor N-
595 device using a finger clip. These findings confirmed the results of our previous study 
[12].  
In conclusion, the revised SenTec digital V-SignTM 2 device attached at the earlobe showed 
considerable improvement in accuracy of PtcCO2 detection. The V-SignTM 2 earlobe sensor is 
a reliable tool for monitoring the ventilation status in respirator dependent and spontaneously 
breathing patients during recovery after cardiac surgery.  
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Figure legends 
 
Fig 1a-c Agreement of PtcCO2 and PaCO2 at the earlobe, the forehead and the check with n = 
296/297/299, mean bias +1.1/ +1.8/+1.5 mmHg and limits of agreement of -3.4;+5.5/-
2.4;+7.8/-3.9;+6.9 mmHg, respectively 
 
Fig 2 PtcCO2ear (thick solid line), PtcCO2 forehead (thin solid line), PtcCO2cheek (thick 
dashed line) and PaCO2 (thin dashed line) at the 16 sample points. Median [25/75% 
percentile] of PtcCO2 at the earlobe, forehead and cheek, PaCO2 were recorded at the sample 
times (n = 20 for each sample time) 
 
Fig 3a-c First differences of PtcCO2 and PaCO2 at the earlobe (r2 = 0.81, p < 0.001) the 
forehead (r2 = 0.73, p < 0.001) and the cheek (r2 = 0.77, p < 0.001)  
 
Fig 4a-c Agreement of V-Sign SpO2 and SaO2 at the earlobe, the forehead and the cheek with 
n = 270/244/225, mean bias -.1.68/ -2.40/-2.04 % and limits of agreement of -6.81;+3.45/-
7.38;+2.57/-6.60;+2.53 %, respectively 
 
Fig 5a-c Agreement of V-Sign PR and PR measured by ECG with n = 285/269/294, mean 
bias +1.22/ +1.61/+1.18 bpm and limits of agreement of -3.31;+5.75/-2.52;+5.73./-4.21;+6.58 
bpm, respectively 
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Tables 
 
Table 1 Patients characteristics and hemodynamic dataa 
___________________________________________________________________________ 
No. of Patients    20 
Age, year     62 ±13.2 (36-84) 
Male/female     16/4 
BMI, kg/m²     26.2 ±4.1 (20.3-36.4) 
Type of surgery 
 CABG     6 
 Valve     11 
  Combined    3 
Cardiac index, liter/min/m²   2.57 ±0.77 (1.0-4.4) 
Mean arterial pressure, mmHg  71 ± 7.6 (58-92) 
Ventilation time, min    297 ± 52 (210-390) 
Intraoperative drug support: 
   *Norepinephrine, g/kg/min   0.07 ± 0.14 (0-0.69) 
 **Epinephrine, g/kg/min    0.04 ± 0.03 (0-0.09) 
***Dobutamine, g/kg/min    1.76 ± 1.76 (0-4.71) 
    °Milrinone, g/kg/min    0.11 ± 0.08 (0.04-0.33) 
___________________________________________________________________________ 
avalues are expressed as mean ±SD (range). Abbreviations: BMI, body mass index; CABG, 
coronary artery bypass graft; *(n = 19 patients), **(n = 3 patients), ***(n = 7 patients), °(n = 
3 patients) 
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Table 2. Agreement between values of non-invasive measurement (V-SignTM 2, Nellcor N-
595) and those of invasive measurements, using linear regression (r²) and Bland-Altman 
analysis 
___________________________________________________________________________ 
 
     n r²  Mean bias  LOA 
___________________________________________________________________________ 
 
PtcCO2ear - PaCO2, mmHg  296 0.92  +1.1   -3.4/+5.5 
 
PtcCO2forehead - PaCO2, mmHg 297 0.85  +1.8   -2.4/+7.8 
 
PtcCO2cheek - PaCO2, mmHg  299 0.88  +1.5   -3.9/+6.9 
 
PECO2  - PaCO2, mmHg  165 0.47  +5.3   -10.9/+21.5 
 
V-Sign SpO2ear – SaO2, %  270 0.59  -1.68   -6.81/+3.45 
 
V-Sign SpO2forehead – SaO2, % 244 0.56  -2.40   -7.38/+2.57 
 
V-Sign SpO2cheek – SaO2, %  225 0.64  -2.04   -6.60/+2.53 
 
N-595 SpO2 – SaO2, %  294 0.73  +0.41   -2.38/+3.19 
 
V-Sign PRear – ECG, bpm  285 0.98  +1.22   -3.31/+5.75 
 
V-Sign PRforehead – ECG, bpm 269 0.98  +1.61   -2.52/+5.73 
 
V-Sign PRcheek – ECG, bpm  282 0.98  +1.18   -4.21/+6.58 
 
N-595 PR – ECG, bpm  294 0.78  +1.00   -16.5/+18.5 
 
___________________________________________________________________________ 
Abbreviations: LOA, limits of agreement; PtcCO2X, transcutaneous carbon dioxide tension measured with V-
Sign sensor at the corresponding measurement site X (ear, forehead, cheek);  PaCO2, arterial carbon dioxide 
tension; V-Sign SpO2X , oxygen saturation measured with V-SignTM 2 sensor at the location X (ear, forehead, 
cheek);   SaO2, arterial oxygen saturation; N-595 SpO2, oxygen saturation measured with the finger clip sensor of 
Nellcor N-595 pulse oximeter; V-Sign PRX, pulse rate measured with V-SignTM 2 sensor; at the location X (ear, 
forehead, cheek) ECG, electrocardiography; N-595 PR, pulse rate measured with the finger clip sensor of Nellcor 
N-595 pulse oximeter. 
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Table 3. Agreement of PtcO2 and PaCO2 during various ventilation states analysed with linear 
regression (r²) and Bland-Altman. 
___________________________________________________________________________ 
 
            n r²  Mean bias LOA 
(mmHg) (mmHg) 
___________________________________________________________________________ 
 
Hyperventilation: 
PtcCO2ear - PaCO2  67 0.82  +1.4  -2.3/+5.0 
PtcCO2forehead - PaCO2 70 0.65  +2..6  -1.1/+6.4 
PtcCO2cheek - PaCO2  70 0.65  +2.3  -1.7/+6.3 
 
Normoventilation: 
PtcCO2ear - PaCO2  192 0.75  +1.1  -3.6/+5.7 
PtcCO2forehead - PaCO2  190 0.65  +1.8  -4.4/+7.8 
PtcCO2cheek - PaCO2  192 0.71  +1.4  -4.3/+7.1 
 
Hypoventilation:  
PtcCO2ear - PaCO2  36 0.76  +0.5  -3.4/+4.4 
PtcCO2forehead - PaCO2  36 0.60  +0.1  -7.3/+7.4 
PtcCO2cheek - PaCO2  36 0.74  +0.3  -5.0/+5.6 
 
___________________________________________________________________________ 
Abbreviations: LOA, limits of agreement; PtcCO2X, transcutaneous carbon dioxide tension measured with V-
SignTM 2 sensor at location X (ear, forehead, cheek);  PaCO2, arterial carbon dioxide tension.  
 
 
 
 
